Insulet’s Omnipod 5 is a tubeless hybrid closed-loop system that delivers insulin doses automatically to help simplify diabetes management. Image credit: Wongsakorn Napaeng / Shutterstock.

Insulet has launched the Omnipod 5 automated insulin delivery app for iPhone in the US. The app obviates the need for carrying a separate controller as it allows users to manage their insulin requirements via the app.

In addition to managing insulin delivery, the app also has a custom food feature that allows users “to input, save, and list carbohydrate counts for their typical meal sizes, favourite foods, and snacks”. It also has a SmartBolous calculator where users can select from a personalised list of foods to determine the amount of insulin required, which can help minimise carb counting and simplify mealtime maths, as per Insulet.

Go deeper with GlobalData

Data Insights

The gold standard of business intelligence.

Find out more

The US Food and Drug Administration (FDA) cleared the iPhone app back in October 2023, more than a year after the Omnipod 5 device was first approved by the FDA for use in patients with type 1 diabetes aged over two years.

The Omnipod 5 is a tubeless hybrid closed-loop system that helps deliver insulin doses automatically to help simplify diabetes management. The Dexcom G6 sends regular blood sugar parameters to the device, which it can then use to adjust insulin delivery doses.

The Omnipod 5 App for iPhone is currently compatible with the Dexcom G6 continuous glucose monitoring (CGM) System. Insulet expects to be compatible with the next-generation Dexcom G7 CGM compatibility in the US next year.

The diabetes care market is expected to grow to be worth $33.5bn in 2030, as per the GlobalData market model. The insulin pump market is projected to reach $14bn in the same period, as per GlobalData analysis.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Insulet also secured label expansion for Omnipod 5 device from the FDA allowing for its use in adult patients with type 2 diabetes. The US label expansion was based on the positive data from the open-label SECURE-T2D clinical trial (NCT05815342).

Omnipod is a high-grossing product for Insulet, it generated $1.7bn in global revenue last year, as per the company’s financials. Insulet expects an 18%-21% growth in total Omnipod revenue for this year compared to 2023, as per the company’s Q2 2024 financials.